newsfilter
← Latest News
GlobeNewswire·

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data